Clinical Trials Logo

Myotonic Dystrophy Type 2 clinical trials

View clinical trials related to Myotonic Dystrophy Type 2.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05854433 Recruiting - Clinical trials for Myotonic Dystrophy Type 2

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

BraCE-DM2
Start date: April 26, 2023
Phase:
Study type: Observational

Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life. Yet, relatively little is known about how DM2 affects brain structure and cognitive function as brain imaging studies in DM2 are extremely limited. This is a prospective, cross-sectional study of brain structure and function on cognitive and motor performance in patients with DM2 compared to healthy controls. All participants will undergo magnetic resonance imaging (MRI) to evaluate brain structure and white matter integrity, a comprehensive battery of cognitive and motor measures, self-reported questionnaires, and blood collection for brain-based biomarker analysis. A subset of participants will undergo lumbar puncture for cerebrospinal fluid (CSF) collection for additional biomarker analysis and validation. This work is critical to inform the development of rigorous clinical trial designs and plan for a longitudinal study to evaluate MRI measures as imaging biomarkers of disease progression and therapeutic response in DM2.

NCT ID: NCT00082108 Recruiting - Muscular Dystrophy Clinical Trials

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

Start date: September 2000
Phase:
Study type: Observational

Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their diseases. The registry will also help scientists to accomplish research on DM and FSHD and to distribute their findings to patients and care providers.